Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yizhun AI is a China-based healthcare AI company focused on artificial intelligence for medical imaging diagnosis and workflow optimization. The company develops commercial software products for lung CT, mammography, breast ultrasound, chest DR, coronary CTA, rib fracture detection, and related radiology use cases, and it also offers an AI research platform called Darwin. Yizhun appears to operate primarily as a medical device software and clinical intelligence company rather than a therapeutic biotech developer, with products deployed across a large network of hospitals in China. The company has highlighted NMPA-cleared products, including breast X-ray and lung nodule AI offerings, and has pursued international expansion through a business alliance with Clairvo in Japan. Overall, Yizhun is best characterized as a commercial-stage medical imaging AI platform company serving providers, imaging centers, and research users.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yizhun Medical AI.